News

Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its ...
The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a ...
Employer health plans brace for ongoing soaring costs as weight-loss drug utilization rises. What trends are coming down the ...
Physicians are turning to other options, including older, cheaper medications, as compounding GLP-1s comes to an end.
Interest in weight-loss medications is at an all-time high, with promising study results and inspiring success stories coming ...
Secretary Robert F. Kennedy Jr. said he is considering a “regulatory framework” for Medicare and Medicaid to cover GLP-1 ...
Now some doctors are trying GLP-1 drugs — popular medications for weight-loss and Type 2 diabetes — as part of lymphedema ...
As obesity rates rise among individuals with T1D, GLP-1 agonist medications, indicated for T2D and weight loss, are ...
Medicare does cover GLP-1 drugs when prescribed for conditions like diabetes and heart disease, but legislation from 2003 ...
Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...
A retrospective study found that women who took a GLP-1 drug for obesity were more likely to be diagnosed with acne vulgaris ...
Five scientists won this year’s Breakthrough Prize in Life Sciences for their work on GLP-1 and the development of drugs for ...